Literature DB >> 18725446

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

José Moltó1, José R Santos, Nuria Pérez-Alvarez, Samandhy Cedeño, Cristina Miranda, Saye Khoo, Laura Else, Josep Maria Llibre, Marta Valle, Bonaventura Clotet.   

Abstract

The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The primary outcome of the study was a viral load (VL) of <50 copies/ml at week 48. The trough concentrations of darunavir in plasma, the number of darunavir resistance mutations, the change in the 50% inhibitory concentration (IC(50)) of darunavir in the virtual phenotype, and the darunavir gIQ and vIQ were correlated with the virological outcome in regression analyses adjusted by the number of active drugs in the background regimen. The VL was <50 copies/ml in 56.8% of patients at week 48. Changes in the VL were not significantly associated with the darunavir concentration (P = 0.304), the number of darunavir resistance mutations (P = 0.695), or the change in the IC(50) (P = 0.750). However, patients with darunavir vIQs of >or=1.5 had a 12-fold greater chance of achieving a >or=1 log(10) reduction in the VL (odds ratio [OR], 12.7; 95% confidence interval [95% CI], 1.9 to 81.6; P = 0.007), and a 5-fold greater chance of achieving a VL of <50 copies/ml (OR, 5.4; 95% CI, 1.2 to 24.5; P = 0.028), at week 48 than patients with darunavir vIQs of <1.5. The positive and negative predictive values of this darunavir vIQ cutoff for achieving a VL of <50 copies/ml at week 48 were 70% and 69%, respectively. The darunavir vIQ predicts virological response to darunavir-based salvage therapy better than the darunavir trough concentration or resistance mutations alone. We suggest targeting a darunavir vIQ of 1.5 for achieving long-term viral suppression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725446      PMCID: PMC2573097          DOI: 10.1128/AAC.00520-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Update of the drug resistance mutations in HIV-1: 2007.

Authors:  Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2007 Aug-Sep

2.  Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

Authors:  Joseph Gathe; David A Cooper; Charles Farthing; Dushyantha Jayaweera; Dorece Norris; Gerald Pierone; Corklin R Steinhart; Benoit Trottier; Sharon L Walmsley; Cassy Workman; Geoffrey Mukwaya; Veronika Kohlbrenner; Catherine Dohnanyi; Scott McCallister; Douglas Mayers
Journal:  Clin Infect Dis       Date:  2006-10-17       Impact factor: 9.079

3.  Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.

Authors:  Pedro Cahn; Jorge Villacian; Adriano Lazzarin; Christine Katlama; Beatriz Grinsztejn; Keikawus Arasteh; Paulo López; Nathan Clumeck; Jan Gerstoft; Nikolas Stavrianeas; Santiago Moreno; Francisco Antunes; Dietmar Neubacher; Douglas Mayers
Journal:  Clin Infect Dis       Date:  2006-10-17       Impact factor: 9.079

4.  Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

Authors:  Daniel Gonzalez de Requena; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

5.  Predictors of virological response to atazanavir in protease inhibitor-experienced patients.

Authors:  Ana Barrios; Ana Lucía Rendón; Oscar Gallego; Luz Martín-Carbonero; Luisa Valer; Pilar Ríos; Ivana Maida; Teresa García-Benayas; Inmaculada Jiménez-Nácher; Juan González-Lahoz; Vincent Soriano
Journal:  HIV Clin Trials       Date:  2004 Jul-Aug

6.  HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

Authors:  Antonio D'Avolio; Marco Siccardi; Mauro Sciandra; Lorena Baietto; Baietto Lorena; Stefano Bonora; Laura Trentini; Giovanni Di Perri
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-07       Impact factor: 3.205

7.  Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Authors:  Anne-Geneviève Marcelin; Claire Lamotte; Constance Delaugerre; Nadine Ktorza; Hocine Ait Mohand; Raquel Cacace; Manuela Bonmarchand; Marc Wirden; Anne Simon; Philippe Bossi; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

9.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lalezari; Anthony Mills; Gilles Pialoux; Timothy Wilkin; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Lorant Leopold; Roberta Trefiglio; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

10.  Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

Authors:  Jean-Michel Molina; Calvin Cohen; Christine Katlama; Beatriz Grinsztejn; Artur Timerman; Rogerio de Jesus Pedro; Tony Vangeneugden; Diego Miralles; Sandra De Meyer; Wim Parys; Eric Lefebvre
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

View more
  10 in total

Review 1.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

2.  Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.

Authors:  Gaik H Soon; Ping Shen; Eu-Leong Yong; Paul Pham; Charles Flexner; Lawrence Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

3.  Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

Authors:  Rob Ter Heine; Jan Willem Mulder; Eric C M van Gorp; Jiri F P Wagenaar; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

4.  Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

Authors:  G Sterrantino; M Zaccarelli; G Colao; F Baldanti; S Di Giambenedetto; T Carli; F Maggiolo; M Zazzi
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

5.  Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

Authors:  Edward P Acosta; Kay L Limoli; Lan Trinh; Neil T Parkin; Jennifer R King; Jodi M Weidler; Ighovwerha Ofotokun; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

Review 6.  Darunavir: a review of its use in the management of HIV infection in adults.

Authors:  Kate McKeage; Caroline M Perry; Susan J Keam
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  Darunavir: a review of its use in the management of HIV-1 infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 11.431

8.  Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.

Authors:  James M Mikula; Chiu-Bin Hsiao; Joshua R Sawyer; Qing Ma; Gene D Morse
Journal:  AIDS Res Treat       Date:  2013-07-17

9.  Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

10.  Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.

Authors:  Jeremiah D Momper; Jiajia Wang; Alice Stek; David E Shapiro; Gwendolyn B Scott; Mary E Paul; Irma L Febo; Sandra Burchett; Elizabeth Smith; Nahida Chakhtoura; Kayla Denson; Kittipong Rungruengthanakit; Kathleen George; Derek Z Yang; Edmund V Capparelli; Mark Mirochnick; Brookie M Best
Journal:  AIDS       Date:  2021-07-01       Impact factor: 4.632

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.